AI Article Synopsis
- Current guidelines suggest using serum M-protein and serum-free light chain analysis (S-FLC) for screening suspected M-protein-related disorders, as relying solely on serum M-protein might lead to missed cases of multiple myeloma.
- In some regions of Denmark, general practitioners are unable to order S-FLC tests, potentially affecting diagnosis.
- This review aims to educate on the importance, uses, and limitations of S-FLC analysis in identifying monoclonal gammopathies.
Article Abstract
Current guidelines recommend screening with serum M-protein and serum-free light chain analysis (S-FLC) when an M-protein-related disorder is suspected. Many patients with multiple myeloma will be overlooked if only serum M-protein is measured. Despite this, the general practitioners in some areas of Denmark cannot order S-FLC. This review aims to disseminate knowledge of the S-FLC analysis, its applicability, and limitations in the diagnostic workup for suspected monoclonal gammopathies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.61409/V12230766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Chinese guidelines on response assessment and minimal residual disease monitoring in multiple myeloma (2024)].
Zhonghua Xue Ye Xue Za Zhi
December 2024
The application of standardized criteria to evaluate treatment efficacy is crucial for guiding therapeutic decisions, assessing prognosis, and interpreting outcomes in treating multiple myeloma (MM). The unique characteristics of MM make its response assessment more complex compared with other malignancies. It primarily depends on serum and urine M protein levels, combined with the number of plasma cells in the bone marrow and comprehensive imaging findings.
View Article and Find Full Text PDFEnhanced detection and Characterization of M-proteins in multiple myeloma patients using An Agilent AssayMAP Bravo liquid handling system coupled to an LC-QTOF.
Clin Biochem
December 2024
Department of Pathology and Laboratory Medicine, London Health Sciences Centre and St. Joseph's Health Care London, London, ON, Canada; Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Background: Mass spectrometry methods are emerging as tools to detect M-proteins in the serum of multiple myeloma patients with increased sensitivity and specificity compared to traditional electrophoretic methods.
Methods: A liquid handling system, the Agilent AssayMAP Bravo, with liquid chromatography high-resolution quadrupole-time-of-flight (LC-QTOF) mass spectrometry to analyze intact light chains was compared to immunofixation electrophoresis (IFE) for M-protein analysis. 210 patient serum samples were analyzed in a split sample comparison (LC-QTOF vs.
A case report of an M protein-negative patient with POEMS syndrome associated with renal involvement.
BMC Nephrol
December 2024
Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518000, China.
Background: POEMS syndrome with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes is an uncommon plasma cell paraneoplastic syndrome involving multiple system. It is relatively rare in clinical practice, and renal involvement is a usual yet easily overlooked symptom.
Case Presentation: We successfully treated a patient with M protein-negative POEMS syndrome with membranoproliferative glomerulonephritis (MPGN) findings and thrombotic microangiopathic changes by comparing the level of Vascular endothelial growth factor (VEGF) in the serum and the changes in polyserositis before and after the patient's treatment.
Urine analysis in monoclonal gammopathies at diagnosis: settling cut-off values.
Adv Lab Med
December 2024
Laboratory Department, Sant Joan Despí Moisès Broggi Hospital, CLILAB Diagnòstics, Barcelona, Spain.
Objectives: Laboratory testing has an extensive role in the diagnosis of monoclonal gammopathies. Since the last updates of the International Myeloma Working Group (IMWG) guidelines for the diagnosis of monoclonal gammopathies, debate has arisen as to whether urine analysis remains relevant for the diagnosis of these entities.
Methods: We carried out a retrospective study with data from 132 patients with a newly diagnosed serum M-protein.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
J Appl Lab Med
December 2024
The Binding Site, part of Thermo Fisher Scientific, Rochester, MN, United States.
Background: Therapeutic monoclonal antibodies (t-mAbs) may interfere with electrophoresis-based methods used to monitor multiple myeloma (MM), which can create inaccurate results. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is an alternative to gels distinguishing between endogenous M-proteins and t-mAbs based on molecular mass.
Methods: Serum samples (n = 109) from 34 MM patients receiving Dara-KRd were collected 14 or 28 days postdaratumumab administration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!